Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer.

Abstract

Thorombospondin-1 (TSP-1) is a 450 kDa extracellular matrix glycoprotein, with anti-angiogenic activity. We analyzed the relationship in TSP-1 expression and Microvessel count (MVC), and also clinical factors, using immunohistochemical methods for non-small cell cancer (NSCLC). Histopathologically, there was inverse correlation between TSP-1 expression and MVC for squamous cell carcinoma, but not for adenocarcinoma cases. Among 199 completely resected cases of NSCLC, the 5-year survival was 77.0% when the expression of TSP-1 was maintained and 55.1% when the expression were reduced, respectively (P=0.0046). When compared with TSP-1 expression in the high MVC subgroup, there was significantly shorter survival time when TSP-1 expression was reduced (P=0.0091), and no significant difference was seen for the low MVC subgroup. Multivariate analysis revealed that expression of TSP-1 is as a prognostic factor of NSCLC. Our present data suggest that TSP-1 might not be a direct anti-angiogenic factor and the TSP-1 expression is a prognostic indicator of NSCLC.

• Authors: Masafumi Yamaguchi, Kenji Sugio, Kaoru Ondo, Tokujiro Yano, Keizo Sugimachi
• Journal: Lung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 36 Issue 2 Pg. 143-50 (May 2002) ISSN: 0169-5002 [Print] Ireland
• PMID: 11955648 (Publication Type: Journal Article)

Chemical References

• Antigens, CD34
• Thrombospondin 1

Topics

• Adult
• Aged
• Aged, 80 and over
• Antigens, CD34 (metabolism)
• Carcinoma, Non-Small-Cell Lung (blood supply, diagnosis, metabolism)
• Cell Differentiation
• Down-Regulation
• Female
• Humans
• Immunoenzyme Techniques
• Lung Neoplasms (blood supply, diagnosis, metabolism)
• Male
• Middle Aged
• Neoplasm Staging
• Neovascularization, Pathologic
• Prognosis
• Survival Rate
• Thrombospondin 1 (metabolism)